APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma

Clin Adv Hematol Oncol. 2003 Mar;1(3):190.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Boronic Acids / therapeutic use*
  • Boronic Acids / toxicity
  • Bortezomib
  • Clinical Protocols
  • Dexamethasone / therapeutic use*
  • Dexamethasone / toxicity
  • Drug Resistance, Neoplasm
  • Humans
  • Multiple Myeloma / drug therapy*
  • Patient Selection
  • Protease Inhibitors / therapeutic use*
  • Protease Inhibitors / toxicity
  • Pyrazines / therapeutic use*
  • Pyrazines / toxicity
  • Recurrence
  • Salvage Therapy / methods*

Substances

  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Bortezomib
  • Dexamethasone